Fluoride side effects: what 575 FDA adverse event reports show
Drug class
Not stated in label
Who reports
575 reports · 27% serious · 3 with death outcome · 68% female
Used for
Directions Adults and children 12 years of age and older: apply at least a 1-inch strip of the product onto a soft bristle toothbruch. brush teeth thorughly for at least one minute for at least twice a day (morning and evening), and not more than 3 times a day, or as directed by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing. Spit out after brushing.
Boxed warning
None in the current label
Causality screen of the 18 strongest signals
What the badges mean
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Oral discomfort | 79 | 206.0 167.7–253.1ROR 238.3 · χ² 15,833 / p <1e-300 | 195.2 EB05 161.7 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=25 · 94% consumer | no trial data cached |
| Toothache | 40 | 80.0 59.3–107.9ROR 85.8 · χ² 3,037 / p <1e-300 | 77.0 EB05 59.0 · IC025 +4.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 104.9 · 100% consumer | no trial data cached |
| Oral pain | 39 | 62.8 46.3–85.0ROR 67.2 · χ² 2,307 / p <1e-300 | 60.9 EB05 46.5 · IC025 +4.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 132.7 · 92% consumer | no trial data cached |
| Product complaint | 36 | 52.1 38.0–71.6ROR 55.5 · χ² 1,754 / p <1e-300 | 50.7 EB05 38.3 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | serious n=12 · 100% consumer | no trial data cached |
| Gingival bleeding | 16 | 42.3 26.1–68.6ROR 43.4 · χ² 604 / p 1e-133 | 40.4 EB05 26.3 · IC025 +3.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 16.9 | no trial data cached |
| Poor quality product administered | 8 | 28.3 14.2–56.3ROR 28.6 · χ² 184 / p 3e-42 | 26.3 EB05 13.8 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=1 | no trial data cached |
| Drug effect less than expected | 10 | 25.6 13.9–47.4ROR 26.0 · χ² 213 / p 2e-48 | 24.3 EB05 13.8 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Drug effective for unapproved indication | 20 | 24.7 16.1–38.0ROR 25.6 · χ² 432 / p 3e-96 | 24.2 EB05 16.5 · IC025 +3.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Dermatitis contact | 7 | 22.3 10.7–46.5ROR 22.5 · χ² 122 / p 1e-28 | 20.0 EB05 8.7 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Dental caries | 6 | 19.6 8.8–43.5ROR 19.8 · χ² 88 / p 3e-21 | 16.4 EB05 6.0 · IC025 +1.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 43.3 | no trial data cached |
| Choking | 10 | 18.6 10.1–34.4ROR 18.9 · χ² 149 / p 1e-34 | 17.3 EB05 9.0 · IC025 +2.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 46.9 | no trial data cached |
| Salivary hypersecretion | 5 | 18.1 7.5–43.3ROR 18.2 · χ² 64 / p 5e-16 | 13.7 EB05 4.4 · IC025 +1.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 31.5 | no trial data cached |
| Paraesthesia oral | 7 | 17.6 8.4–36.7ROR 17.8 · χ² 94 / p 2e-22 | 15.0 EB05 6.1 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 28.8 | no trial data cached |
| Expired product administered | 16 | 17.4 10.7–28.2ROR 17.9 · χ² 232 / p 1e-52 | 16.8 EB05 10.5 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious n=4 | no trial data cached |
| Glossodynia (burning tongue/mouth pain) | 9 | 14.5 7.6–27.8ROR 14.7 · χ² 100 / p 6e-24 | 12.5 EB05 5.9 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 20.0 | no trial data cached |
| Lip swelling | 12 | 13.0 7.4–22.8ROR 13.3 · χ² 122 / p 1e-28 | 11.5 EB05 6.2 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 26.0 | no trial data cached |
| Tooth disorder | 8 | 12.9 6.5–25.7ROR 13.1 · χ² 77 / p 1e-18 | 10.3 EB05 4.7 · IC025 +1.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 18.0 | no trial data cached |
| Accidental exposure to product | 10 | 3.6 2.0–6.7ROR 3.7 · χ² 16 / p 2e-5 | 3.2 EB05 1.9 · IC025 +0.6 | Reporting / coding artifact | serious PRR 43.7 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Oral discomfort | 79 | 206.0 167.7–253.1ROR 238.3 · χ² 15,833 / p <1e-300 | 195.2 EB05 161.7 · IC025 +6.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=25 · 94% consumer | no trial data cached |
| Toothache | 40 | 80.0 59.3–107.9ROR 85.8 · χ² 3,037 / p <1e-300 | 77.0 EB05 59.0 · IC025 +4.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 104.9 · 100% consumer | no trial data cached |
| Oral pain | 39 | 62.8 46.3–85.0ROR 67.2 · χ² 2,307 / p <1e-300 | 60.9 EB05 46.5 · IC025 +4.6 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 132.7 · 92% consumer | no trial data cached |
| Product complaint | 36 | 52.1 38.0–71.6ROR 55.5 · χ² 1,754 / p <1e-300 | 50.7 EB05 38.3 · IC025 +4.4 3/3 methods agree | Reporting / coding artifact | serious n=12 · 100% consumer | no trial data cached |
| Drug effective for unapproved indication | 20 | 24.7 16.1–38.0ROR 25.6 · χ² 432 / p 3e-96 | 24.2 EB05 16.5 · IC025 +3.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | – | no trial data cached |
| Expired product administered | 16 | 17.4 10.7–28.2ROR 17.9 · χ² 232 / p 1e-52 | 16.8 EB05 10.5 · IC025 +2.7 3/3 methods agree | Reporting / coding artifact | serious n=4 | no trial data cached |
| Gingival bleeding | 16 | 42.3 26.1–68.6ROR 43.4 · χ² 604 / p 1e-133 | 40.4 EB05 26.3 · IC025 +3.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 16.9 | no trial data cached |
| Lip swelling | 12 | 13.0 7.4–22.8ROR 13.3 · χ² 122 / p 1e-28 | 11.5 EB05 6.2 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 26.0 | no trial data cached |
| Accidental exposure to product | 10 | 3.6 2.0–6.7ROR 3.7 · χ² 16 / p 2e-5 | 3.2 EB05 1.9 · IC025 +0.6 | Reporting / coding artifact | serious PRR 43.7 | no trial data cached |
| Choking | 10 | 18.6 10.1–34.4ROR 18.9 · χ² 149 / p 1e-34 | 17.3 EB05 9.0 · IC025 +2.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 46.9 | no trial data cached |
| Drug effect less than expected | 10 | 25.6 13.9–47.4ROR 26.0 · χ² 213 / p 2e-48 | 24.3 EB05 13.8 · IC025 +2.5 3/3 methods agree | Reporting / coding artifact | – | no trial data cached |
| Glossodynia (burning tongue/mouth pain) | 9 | 14.5 7.6–27.8ROR 14.7 · χ² 100 / p 6e-24 | 12.5 EB05 5.9 · IC025 +1.9 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 20.0 | no trial data cached |
| Tooth disorder | 8 | 12.9 6.5–25.7ROR 13.1 · χ² 77 / p 1e-18 | 10.3 EB05 4.7 · IC025 +1.7 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 18.0 | no trial data cached |
| Poor quality product administered | 8 | 28.3 14.2–56.3ROR 28.6 · χ² 184 / p 3e-42 | 26.3 EB05 13.8 · IC025 +2.2 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious n=1 | no trial data cached |
| Paraesthesia oral | 7 | 17.6 8.4–36.7ROR 17.8 · χ² 94 / p 2e-22 | 15.0 EB05 6.1 · IC025 +1.8 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 28.8 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Fluoride?
In FDA FAERS, the most frequently co-reported reaction terms for Fluoride are oral discomfort, toothache, oral pain, drug effective for unapproved indication, gingival bleeding, lip swelling. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Fluoride have an FDA boxed warning?
No. The FDA label retrieved for Fluoride has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Fluoride causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 18295a1c-c2a6-489b-be34-9252b9e1e2b8, effective 20251121; matched on
openfda.generic_name.exact:"FLUORIDE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 19 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.